InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the complete record of transactions filed by Cooper Matthew T, Directeur Scientifique. Insider active across 2 companies, notably Progenity, INC.. Aggregated, 6 disclosures have been logged. History available since 15 May 2021. The latest transaction was filed on 15 November 2021 (Retenue fiscale). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
700 shares@ US$3.4724.8% of flowCommon StockSEC:0000899243-21-045044:0
700 shares@ US$3.4772.9% of flowCommon StockSEC:0000899243-21-045044
560 shares@ US$1.669.2% of flowCommon StockSEC:0000899243-21-033251
560 shares@ US$1.669.2% of flowCommon StockSEC:0000899243-21-033251:0
1,400 shares@ US$2.3632.0% of flowCommon StockSEC:0000899243-21-019668:0
1,400 shares@ US$2.36100.0% of flowCommon StockSEC:0000899243-21-019668
6 of 6 declarations
About Cooper Matthew T
Matthew T. Cooper is the Chief Scientific Officer and General Manager, Diagnostics at Progenity, Inc. In his role, he is responsible for the scientific direction and innovation within the company. His expertise is essential for the development of advanced diagnostic solutions at Progenity.
